A panel of federal advisers told the FDA that it should approve Kynapid but reject Pulzium to treat atrial fibrillation, a condition in which the two uppermost chambers of the heart beat irregularly and at an extremely rapid rate. (BioWorld Today)

FDA Panel OKs Kynapid, But Votes Against Pulzium

Dec. 13, 2007

By Donna Young

Study Links ESAs To Higher Leukemia Risk For Some

Dec. 12, 2007

By Donna Young

Erythropoiesis-stimulating agents (ESAs), such as Aranesp, Epogen and Procrit, may increase the risk of acute leukemia in patients with a certain bone marrow disorder, researchers reported at the American Society of Hematology's annual meeting in Atlanta. (BioWorld Today)

Study Links ESAs To Higher Leukemia Risk For Some

Dec. 12, 2007

By Donna Young

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...